Drug search by name

Adynovate and Inhibitory antibodies

Result of checking the interaction of drug Adynovate and disease Inhibitory antibodies for safety when used together.

Check result:

Adynovate <> Inhibitory antibodies

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The formation of neutralizing antibodies (inhibitors) to Factor VIII may occur. Subsequent administration of either antihemophilic factor can result in anamnestic response and increased levels of inhibitor. Response to treatment with antihemophilic factor may be less than expected. Cross-reactivity between human and recombinant agents has been noted. It is recommended to carefully monitor patients for the development of factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled, perform an assay that measures factor VIII inhibitor concentration to determine if a factor VIII inhibitor is present. Clinical assessment of patient history, severity of bleeding and inhibitor level (history and current) is necessary.

References:

"Product Information. Koate-HP (antihemophilic factor)." Bayer, West Haven, CT.

Adynovate

Generic Name: antihemophilic factor

Brand Name: Advate, Adynovate, Afstyla, Eloctate with Fc Fusion Protein, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil-M, Koate-DVI, Monoclate-P, Jivi, Obizur

Synonyms: Adynovate (recombinant)

What is Adynovate?